Critical
Everolimus × Voriconazole
mTOR kinase inhibitor – immunosuppressant and antineoplastic×Triazole derivatives, systemic antifungals
Mechanism
Strong CYP3A4 inhibitor. Everolimus rises 9-fold.
Symptoms
Immunosuppression, nephrotoxicity.
Management
Combination contraindicated.
Check the full regimen, not just this pair
Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.
Sources
- FDA: Vfend (voriconazole) prescribing information – CYP3A4 inhibitor, statin/immunosuppressant interactions (2020)– FDA Vfend label, Drug Interactions §7 – tacrolimus, cyclosporine, sirolimus, statins
- FDA: Afinitor (everolimus) prescribing information – strong CYP3A4 inhibitor restriction (2020)– FDA Afinitor label, Drug Interactions §7.1
- EMA: Certican (everolimus) SmPC (2024)– EMA EPAR Certican